Lab News

Jakobi, a previous rotation student from the MMI program, and Lina, our undergraduate researcher and lab manager, presented their work at the M3 Meetup: Symposium in Engineering and Analytics in Microbiome Research at the University of Maryland. M3 is a regional meeting that brings together microbiome scientists to share advances in engineering, computational analytics, and experimental approaches to studying complex microbial communities. Their work focused on identifying gut microbiome-derived metabolites associated with epinephrine use and adverse reactions during peanut oral immunotherapy. 

Our laboratory has received support through a NIAID-DP2 NIH Director’s New Innovator Award, part of the NIH High-Risk, High-Reward Research Program. This award will support research investigating how the early-life gut microbiome influences food allergy development and resolution, with an emphasis on translational applications.

We acknowledge the support of NIH and NIAID, as well as collaborators who contributed to this work. In addition, we thank the Immune Tolerance Network for providing clinical samples central to this study. This funding will support efforts to address knowledge gaps in microbiome and food allergy research while contributing to the training of researchers in this area.

Mustafa recently joined the Breaking Down Biology blog and podcast to discuss research exploring how the gut microbiome may influence outcomes of peanut oral immunotherapy (POIT).

The interview highlights findings from the Immune Tolerance Network IMPACT clinical trial, which identified links between gut microbial metabolism, bile acid profiles, and treatment response. This feature provides an accessible overview of the study design, key findings, and clinical implications for microbiome-informed strategies to improve food allergy therapies.

We are excited to share our recent publication in Nature Communications titled Gut microbial bile and amino acid metabolism associate with peanut oral immunotherapy failure. Using integrated multi-omics analyses of samples from the IMPACT clinical trial, this study demonstrates that gut microbiome metabolic activity prior to treatment can predict peanut oral immunotherapy outcomes and reveals microbial protein and bile acid metabolism as potential mechanisms underlying treatment failure. These findings highlight the importance of microbiome-derived metabolic functions as biomarkers and therapeutic targets to improve food allergy immunotherapy efficacy.